JOINT BONE SPINE关节骨脊柱
JOINT BONE SPINE(英文缩写 JOINT BONE SPINE),ISSN 1297-319X,eISSN 1778-7254,中文译名:关节骨脊柱 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 5.263 | Q2 |
| 2022 | 4.200 | Q2 |
| 2023 | 3.800 | Q1 |
| 2024 | 4.300 | Q1 |
| 2025 | 5.000 | Q1 |
JOINT BONE SPINE 最新收录文献
-
1. Residual Glucocorticoid Use at Boolean Remission in Rheumatoid Arthritis: An analysis of the FRANK Registry.
PMID:日期:2026-09-21Glucocorticoids (GCs) are recommended as short-term bridging therapy in rheumatoid arthritis (RA), yet many patients continue long-term GC use, raising safety concerns. This study evaluated the effectiveness and safety of residual GC use at the time of achieving Boolean remission. Data were obtained from the Fukuoka Rheumatoid Arthritis Network (FRANK) registry, a multicentre prospective registry. We included 411 patients who newly achieved Boolean remission between 2018 and 2023. Patients were classified as GC non-users or users based on concomitant oral GC use at remission. Propensity score-based inverse probability of treatment weighting (IPTW) was adjusted for baseline confounders. The primary outcome was time to loss of Boolean remission. Secondary outcomes included longitudinal changes in the Clinical Disease Activity Index (CDAI), modified Health Assessment Questionnaire (mHAQ), and EuroQol 5-dimension (EQ-5D) scores. Safety outcomes included the incidence of herpes zoster, acute coronary syndrome, and stroke. After IPTW adjustment, baseline characteristics were well balanced between 281 GC non-users and 130 GC users. No significant difference was observed in the time to loss of remission. Longitudinal trajectories of CDAI, mHAQ, and EQ-5D scores were comparable between groups. Although the very low number of events precludes definitive conclusions, safety events were numerically higher in GC users. Residual GC use at remission did not improve remission maintenance. Given the lack of additional clinical benefit and the numerical trend toward higher safety events, GC-free remission is the true therapeutic goal, highlighting the need to overcome reliance on GCs through active tapering and discontinuation.
-
2. Efficacy and Tolerance of a Combination of Targeted Therapies Indicated for Asthma and Chronic Inflammatory Rheumatism.
PMID:日期:2026-09-19The use of combined targeted therapies is increasing in clinical practice, both within and across diseases. However, data on dual targeted therapy for patients with both chronic inflammatory rheumatism (CIR) and severe allergic asthma remain limited, especially regarding treatment outcomes and safety, including infection risk. The objective of this study was to assess the impact of this combination on the course of both chronic inflammatory diseases as well as their safety profile. This retrospective, observational study included patients treated with dual targeted therapies for CIR and asthma from December 2020 to June 2023. Each distinct therapeutic combination was analyzed individually. This study was carried out in collaboration with rheumatologists and pulmonologists from multiple French hospital centers. A total of 19 therapeutic combinations were analyzed in 16 patients, including 11 with rheumatoid arthritis (68.8%) and 4 with spondyloarthritis (25%). Rheumatologic treatments included mainly anti-cytokine therapies used in 11 patients (57.9%) (7 with TNFα antagonists, 3 with anti-IL17 antibodies and 1 with tocilizumab) and 8 patients (42.1%) with another mode of action (4 with abatacept, 3 with JAK inhibitors, and 1 with rituximab). Asthma therapy involved anti-IL5 receptor biologics in 15 patients (78.9%). The mean duration of dual therapy was 14.2 ± 8.4 months. Four combinations (21.1%) required modification of the rheumatologic treatment, three cases (15.8%) due to inadequate disease control and one due to remission of CIR (5.25%). Three other combinations (15.8%) were modified due to poor asthma control, and three (15.8%) due to adverse events. Overall, 11 out of 19 combinations (57.9%) were associated with adverse events, including 7 serious events (63.6%). The most frequent were respiratory infections (5 cases). This is the largest case series to date on dual targeted therapy for CIR and allergic asthma. Rheumatologic control was generally maintained, particularly when rheumatologic treatment was initiated first. Pulmonary infections were the main adverse events, highlighting the need for caution in patients with additional pulmonary comorbidities.
-
3. Weight change and longitudinal disease activity in rheumatoid arthritis: a real-world cohort study.
PMID:日期:2026-09-19To assess whether weight change during routine clinical care is associated with DAS28-CRP trajectories in rheumatoid arthritis (RA) with obesity. Retrospective cohort study of data from Montpellier University Hospital. Adults with RA and obesity (BMI ≥30 kg/m²) were included. Weight change (percentage from baseline) was summarised for each patient as a regression-based slope using all available weight measurements. Outcomes were repeated DAS28-CRP, DAS28-CRP components, remission (DAS28-CRP <2.6) and low disease activity (≤3.2). Mixed-effects models estimated weight change-by-time interactions with prespecified adjustment. Missing data were handled using multiple imputation. Sensitivity analyses included categorical weight-change modelling, a 6-month landmark design, and censoring at DMARD change. Among 106 participants with estimable weight change (24 with ≥5% loss, 64 stable, 18 with ≥5% gain), mean BMI was 33.7 kg/m² and obesity was class I in 76 (71.7%). The weight-change-by-time interaction for DAS28-CRP was null (-0.004 units/year per 5% weight change, 95% CI -0.026 to 0.018). Weight change was not associated with remission (OR 1.01 per 5%, 95% CI 0.96 to 1.06) or low disease activity (OR 1.00 per 5%, 95% CI 0.94 to 1.07), and no signal was observed for DAS28-CRP components. Sensitivity analyses were consistent (weight loss ≥5% vs stable: +0.021 units/year, 95% CI -0.076 to 0.119; weight gain ≥5% vs stable: -0.003 units/year, 95% CI -0.158 to 0.153). In RA with predominantly class I obesity, we did not observe a clear association between routine clinical care weight change and improved inflammatory disease activity. These findings should be interpreted cautiously given the modest sample size and limited precision, and small clinically meaningful effects cannot be excluded.
-
4. Infection Risk Associated with Steroid-Sparing Therapies in GCA, PMR, and ANCA-Associated Vasculitis: A Systematic Review.
4. 巨细胞动脉炎、风湿性多肌痛和ANCA相关性血管炎中激素节约治疗相关的感染风险：系统评价PMID:日期:2026-09-19Giant cell arteritis (GCA), polymyalgia rheumatica (PMR), and ANCA-associated vasculitis (AAV) often require prolonged glucocorticoid therapy. Steroid-sparing biologic and small molecule therapies reduce glucocorticoid exposure, but may increase infection risk, particularly in older adults. We evaluated infection risk associated with these therapies with concomitant glucocorticoid treatment, versus glucocorticoid treatment alone, in vasculitis/PMR clinical trials. We searched PubMed, Embase, Cochrane, and ClinicalTrials.gov using terms related to GCA, PMR, AAV, biologics (tocilizumab, sarilumab), small molecule therapies (upadacitinib, avacopan), glucocorticoids, and infection outcomes. We included randomized controlled trials (RCTs) comparing biologics or small molecules plus glucocorticoid (active intervention) versus glucocorticoid monotherapy (comparator) reporting infection outcomes. We calculated the relative risk (RR) of infection and difference in glucocorticoid dose between the comparator and active intervention groups. We included 10 RCTs (1,487 patients total, enrolling adults averaged ≥50 years): 4 tocilizumab, 3 avacopan, 2 sarilumab, and 1 upadacitinib. When the active intervention had much lower glucocorticoid dosing than the comparator, the RR for infection was either close to 1 or <1. When the active intervention glucocorticoid dose was comparable to the comparator, the RR for infection was >1. Steroid-sparing therapies reduced glucocorticoid exposure with varying magnitudes but were not consistently associated with lower infection risk. These findings underscore the heightened risk of infection when these novel therapies are used in combination with glucocorticoids when the glucocorticoid dose cannot be adequately tapered, particularly in older adults.
-
6. Lower Socioeconomic Status is Associated with a More Severe Course of Rheumatoid Arthritis; a 7-year Follow-Up Study.
PMID:日期:2026-09-18There is a strong association between low socioeconomic status (SES) and rheumatoid arthritis (RA) outcomes. Yet the association of SES with disease activity and SDFR on the long term, within a contemporary, well-treated cohort and potential mechanisms underlying this association are not fully explored. We therefore investigated long-term disease outcomes in RA and studied SES-related mediators that contribute to the impact of SES on RA severity. 789 RA-patients from the Leiden Early Arthritis Clinic were followed for 7 years. SES was defined as educational attainment, categorized as low, intermediate or high. Over time we assessed RA severity using disease activity score-44 (DAS44), the percentage of patients achieving Boolean remission, and the chance of achieving SDFR (sustained absence of synovitis after discontinuing DMARDs ≥1 year). We performed mediation analyses on the association between SES and DAS44 at diagnosis, using patient delay, BMI, smoking and work-related physical strain as potential mediators. At diagnosis and over time, low SES patients compared to high SES patients had higher DAS44 (β=0.37,95%CI:0.18-0.56,p<0.001, β=0.36,95%CI:0.22-0.49,p<0.001), achieved Boolean remission less often (OR=0.52,95%CI:0.37-0.75,p<0.001), yet had a similar chance of achieving SDFR (HR=1.0,95%CI:0.7-1.5,p=non-significant). The higher DAS44 in patients with low SES was not mediated by patient delay, BMI, smoking or work-related physical strain. RA-patients with low SES maintained higher DAS44 throughout the disease course and were less likely to achieve Boolean remission. General SES-related factors (patient delay, BMI, smoking and work-related physical strain) did not explain the association with SES, leaving the SES-related causal factor still unknown.
-
7. Current Diagnostic Pathways for Rheumatoid Arthritis-Associated Interstitial Lung Disease Result in Substantial Underdiagnosis and Excess Mortality: A Multicenter Norwegian Quality Assurance Audit.
PMID:日期:2026-09-01Recent guidelines suggest risk-stratified screening for rheumatoid arthritis-associated interstitial lung disease (RA-ILD). However, the diagnostic gap between current routine care and this screening approach remains unquantified. We assessed currently detected RA-ILD in Norway, benchmarking findings against recent screening-based estimates of the true disease burden. This 10-year quality assurance audit across six centers covered 43% of the Norwegian population. RA-ILD cases identified via ICD-10 codes were confirmed by manual chart review. Prevalence was calculated relative to a registry-derived total RA background population and benchmarked against a 10% expected target derived from recent prospective studies. Mortality was compared to a 3:1 frequency-matched RA control group using Cox proportional hazards regression. Among 17,305 RA patients, 188 (1.1%) had verified ILD; when benchmarked against an expected 10% prevalence, this indicates an 89% diagnostic gap in routine clinical care. Mean age at ILD detection was 67.5 years. Most cases (93.6%) possessed ≥2 established risk factors for RA-ILD: 93.6% were seropositive, 76.1% had smoking histories, while RA onset age ≥60 and persistently increased inflammatory laboratory markers were present in over half of patients. RA-ILD was associated with significantly increased mortality; 66 (4.1/100 person-years) deaths occurred in the RA-ILD group vs. 120 (2.3/100 person-years) among RA controls (HR 1.77; 95% CI: 1.31-2.39, p<0.001). When comparing to prevalence expectations, current routine care may leave a substantial proportion of cases undetected, primarily capturing a high-risk phenotype with excess mortality. Systematic, risk-stratified screening is needed to bridge this diagnostic gap, aiming to enable earlier intervention.
-
8. Residual activated Th17 cells during inactive disease or low disease activity are associated with subsequent disease worsening in radiographic axial spondyloarthritis: a pilot study.
PMID:日期:2026-09-01To investigate whether residual activated T helper 17 (Th17) cells during inactive disease or low disease activity (LDA) in radiographic axial spondyloarthritis (r-axSpA) are associated with subsequent disease instability. Patients with r-axSpA in inactive disease or LDA (Axial Spondyloarthritis Disease Activity Score [ASDAS]<2.1) were included. Peripheral blood mononuclear cells obtained at baseline were analyzed using multicolor flow cytometry. Activated Th17 cells were defined as CD3CD4CXCR3CCR6CD38HLA-DR cells. Patients were categorized into activated Th17-high and activated Th17-low groups according to the receiver operating characteristics-derived cut-off value of activated Th17 cells among CD4 T cells. ASDAS was assessed at baseline, 3 months, and 6 months. ASDAS trajectories were analyzed using linear mixed-effects models, and the proportion of patients experiencing loss of LDA (ASDAS≥2.1) was compared between groups. Twenty-one patients with r-axSpA were included (activated Th17-high, n=9; activated Th17-low, n=12). The activated Th17-high group showed a significantly worse ASDAS trajectory during follow-up than the activated Th17-low group (P for interaction<0.05). Loss of LDA occurred in 4 patients (44.4%) in the activated Th17-high group and in none in the activated Th17-low group (P<0.05). Baseline disease activity status (inactive disease [ASDAS<1.3] vs. LDA [1.3≤ASDAS<2.1]) was not associated with differences in ASDAS trajectories (P for interaction=non-significant) or loss of LDA (P=non-significant). Residual activated Th17 cells during inactive disease or LDA are associated with subsequent disease worsening in r-axSpA. Cellular immune profiling may help identify patients at risk of disease instability despite apparent clinical control.
-
9. Hypermobile Ehlers-Danlos Syndrome and Widespread Pain: Beyond Structural Laxity.
PMID:日期:2026-08-31该文献暂无摘要。
-
10. Plasma Metabolic and Proteomic Signatures of Mixed Exposure to Ambient Air Pollutants Associated with Incident Arthritis Subtypes.
PMID:日期:2026-08-31The associations between ambient air pollution mixtures, related metabolic and proteomic signatures, and arthritis subtypes, including rheumatoid arthritis (RA), osteoarthritis (OA), gout, and psoriatic arthritis (PsA), remain unclear. This prospective cohort study included 401,676 UK Biobank participants free of arthritis at baseline. Air pollution mixture exposure was quantified using Weighted Quantile Sum (WQS) regression. Metabolic and proteomic signatures were derived using multivariable linear and elastic net regression. Associations with incident arthritis were evaluated using Cox proportional hazards models and generalized propensity score approaches. Causal mediation analysis was performed to assess mediating effects. Over a median follow-up of 13 years, 78,188 any type of arthritis cases were identified. The primary contributors to the WQS mixture index were NOx and NO₂ for RA, PM for OA, NOx and PM for gout, and PM and PM for PsA. Higher WQS index scores and their associated metabolic and proteomic signatures were associated with increased risks of arthritis subtypes. These signatures mediated the associations between air pollution mixtures and arthritis risk, with mediation proportions ranging from 4.92% to 35.05%. Top 10 mediating metabolites and proteins showed partial overlap, alongside disease-specific profiles across arthritis subtypes. Air pollution mixtures were associated with increased risks of arthritis subtypes, potentially through both shared and disease-specific metabolic and proteomic pathways, highlighting the importance of considering pollutant mixtures and disease heterogeneity in arthritis research and prevention.